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Available online 16 April 2016Food allergy has rapidly increased in prevalence, suggesting an important role for environmental factors in dis-
ease susceptibility. The immune response of food allergy is characterized by IgE production, and new ﬁndings
from mouse and human studies indicate an important role of the cytokine IL-9, which is derived from both T
cells andmast cells, in diseasemanifestations. Emerging evidence suggests that route of exposure to food, partic-
ularly peanut, is important. Exposure through the skin promotes sensitization while early exposure through the
gastrointestinal tract promotes tolerance. Evidence frommouse studies indicate a role of the microbiome in de-
velopment of food allergy, which is supported by correlative human studies showing a dysbiosis in food allergy.
There is no approved treatment for food allergy, but emerging therapies are focused on allergen immunotherapy
to provide desensitization,while pre-clinical studies are focused on using adjuvants or novel delivery approaches
to improve efﬁcacy and safety of immunotherapy.
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Food allergy is deﬁned as “an adverse health effect arising from a
speciﬁc immune response that occurs reproducibly on exposure to a givenBox 1198, One Gustave L. Levy
, NY 10029, USA.
. This is an open access article underfood” (Boyce et al., 2010) or as “an adverse reaction to food in which im-
munologic mechanisms have been demonstrated” (Muraro et al., 2014).
This deﬁnition includes acute IgE-mediated type-I hypersensitivity re-
actions, such as hives, wheezing, or vomiting after exposure to common
allergens such as peanut, milk, or egg. In addition, there are non-IgE-
mediated food allergies that are characterized by delayed gastrointesti-
nal reactions to foods, such as food protein induced enterocolitis syn-
drome (FPIES) or proctocolitis. Eosinophilic gastrointestinal disorders
(EGID) are also commonly triggered by foods. This review will focusthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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understood category of food allergy. Readers are referred to recent
reviews on the pathophysiology of FPIES (Berin, 2015) or EGID
(Rothenberg, 2015). (See Table 1.)
Food allergy is increasing in prevalence (Savage and Johns, 2015) for
reasons that are not yet clear. A rigorous population-based study utiliz-
ing food challenges to demonstrate food allergy showed that approxi-
mately one in 10 Australian children had a food allergy at one year of
age (Osborne et al., 2011). Estimates in the US and Canada indicate a
prevalence rate of 1 in 15 to 1 in 20 (Soller et al., 2012; Sicherer and
Sampson, 2014). Factors such as hygiene and lack of exposure tomicro-
bial factors, composition of the intestinal microbiota, diet, obesity, Vita-
min D, and environmental chemical exposure have all been proposed to
contribute to this alarming rise in the rate of food allergy in countries
with a Westernized lifestyle. This review will review recent advances
in our understanding of the pathophysiology of food allergy, and identi-
fy new approaches for the treatment of food allergy.
2. Mechanism of anaphylaxis
IgE-mediated food allergy is triggered by allergen cross-linking of
IgE bound to the surface of mast cells or basophils, as in a typical type
I hypersensitivity reaction. The most severe manifestation of food aller-
gy is anaphylaxis, which is an acute reaction affecting 2 or more organ
systems that can be life threatening (Kim and Fischer, 2011; Muraro
et al., 2014; Simons and Sampson, 2015). Although IgE-mediated activa-
tion of tissuemast cells and circulating basophils is thought to represent
the major source of mediators that contribute to the pathology of ana-
phylaxis (Kalesnikoff and Galli, 2010), other cell types such as neutro-
phils and macrophages and other antibody isotypes such as IgG have
been described to contribute to anaphylaxis (Jonsson et al., 2011;
Tsujimura et al., 2008; Strait et al., 2002). The existence of these alterna-
tive pathways of anaphylaxis has not yet been described in humans.
Histamine correlates with anaphylaxis severity (Brown et al., 2013)
and histamine receptor blockers are the ﬁrst line treatment to relieveTable 1
Glossary of food allergy related terms.
Term Deﬁnition
IgE-mediated
food
allergy
Adverse reaction to a food source mediated by the
cross-linking of speciﬁc IgE bound to mast cells and basophils
through FcεRI.
Non-IgE mediated
food allergy
Adverse reaction to a food source that is not mediated by IgE.
Symptoms are typically delayed (hours) and are thought to be
cell mediated.
Anaphylaxis Acute, systemic reaction that can occur within minutes of
exposure and includes symptoms such as vomiting, skin rash,
rapid and weak pulse, abdominal pain, swollen throat, trouble
breathing or swallowing, diarrhea, chest tightness.
Sensitized Having positive IgE to the allergen, with or without symptoms
Allergic Sensitized individual with allergic symptoms to the allergen
Th2 T helper cells producing IL-4 and IL-13
Tfh T helper cells homing to lymph node follicles (and identiﬁed
as CXCR5+) and enabling B cell isotype switching
Treg Regulatory T cell, mostly commonly a CD4+ T cell expressing
the transcription factor Foxp3
Epithelial
cytokines
TSLP, IL-33, IL-25 are epithelial-derived cytokines that can
promote the generation of Th2 cells
Allergen-speciﬁc
immunotherapy
Prolonged treatment consisting in the administration of
increasing amount of a speciﬁc allergen to reduce symptoms.
It can be applied by different routes:
SLIT Sublingual immunotherapy: the allergen is given as drops
under the tongue.
OIT Oral immunotherapy: the allergen is administered orally.
EPIT Epicutaneous immunotherapy: the antigen is applied on the
skin using a patch or similar device.
Desensitization Clinical non-responsiveness while antigen-speciﬁc
immunotherapy is maintained
Clinical tolerance Sustained clinical non-responsiveness to food allergen after
discontinuation of therapymild to moderate allergy symptoms. In addition, platelet-activating fac-
tor (PAF) shows a pivotal role as a mediator of anaphylaxis in mice
(Arias et al., 2009) as well as in humans (Vadas et al., 2012), where
levels correlate with anaphylaxis severity. PAF receptor antagonists,
which inhibit the binding of PAF to the receptor, reduce mortality asso-
ciated with anaphylaxis in animal models (Arias et al., 2009), and deﬁ-
ciency of PAF-AH (PAF acetylhydrolase), the enzyme that inactivates
PAF, predisposed patients to severe anaphylaxis (Vadas et al., 2008),
demonstrating the role of this pathway.
3. Immune proﬁle of food allergy
Despite the fact that IgE plays a central role in the pathogenesis of
food allergy, measurement of food-speciﬁc IgE is not diagnostic in isola-
tion. Quantiﬁcation of food-speciﬁc IgE antibody levels in serum can
identify patients in the pediatric population who are highly likely
(N95%) to experience clinical reactions to egg,milk, peanut or ﬁsh, as re-
cently reviewed (Chokshi and Sicherer, 2016). However lower levels
poorly discriminate between those who are sensitized versus allergic.
Detection of IgE reactivity against components of food (for example
the protein allergenAra h 2 in peanut or Cor a 14 for hazelnut) improves
speciﬁcity (Klemans et al., 2015; Beyer et al., 2015; Eller and
Bindslev-Jensen, 2013). Ara h 2 is digestion-resistant and can trigger
systemic reactionswhile Ara h 8 is cross-reactivewith birchpollen aller-
gens (and can result in positive IgE to peanut in birch pollen-allergic in-
dividuals), is susceptible to digestion, and does not trigger systemic
reactions. IgE levels against whole peanut extract would not discrimi-
nate between IgE to these two allergens with differing potential to trig-
ger reactions. Antibody isotypes other than IgE, such as IgG and IgA, are
not predictive of food allergy. However, ratio of egg white allergen-
speciﬁc IgE/IgG4 has been shown to be better than IgE levels alone in
predicting clinical reactivity to egg (Okamoto et al., 2012; Caubet
et al., 2012).
For the production of IgE antibodies, B cells require help from
allergen-speciﬁc T cells producing IL-4, either Th2 or T follicular helper
(Tfh) cells. T cells from allergic patients display a uniquely Th2 cytokine
production proﬁle (Prussin et al., 2009). IL-9 production from a T cell
subset distinct from those producing IL-5 was recently reported to dif-
ferentiate between children with peanut allergy and children with pea-
nut sensitization (Brough et al., 2014). In addition, it was recently
reported in mice that a population of intestinal mast cells express IL-9,
promote experimental food allergy in an IL-9-dependent manner, and
are dependent on Th2 cells for their development (Chen et al., 2015).
Furthermore, the authors showed that in patients with food allergy, du-
odenal biopsies had elevated expression of genes associated with the
mast cell signature (IL-9, IL-13, chymase, and tryptase). Thus innate
events in the intestinal tissue may be critical for linking systemic Th2-
skewed adaptive responses to symptoms.
Food allergy is commonly referred to as a failure of oral tolerance, a
systemic state of antigen-speciﬁc immune suppression that is mediated
by regulatory T cells. However, there is little information on the role of
Tregs in food allergy. Inmousemodels, administration of Tregs can sup-
press food allergy (Burton et al., 2014). Furthermore, inmice genetically
susceptible to food allergy there is an impairment of Treg function, and
evidence of Th2 reprogramming such that Tregs contribute to Th2 cyto-
kine production rather than suppress it (Noval Rivas et al., 2015). This
was also observed in peripheral blood of subjects with milk allergy
(Noval Rivas et al., 2015), supporting the hypothesis that food allergy
is a failure of regulatory T cells.
4. Emerging evidence for the role of the skin in food allergy
There is growing evidence pointing to the skin as the main site of
sensitization to food allergens, particularly peanut. The majority of pa-
tients with peanut or tree nut allergy experienced their ﬁrst reaction
the ﬁrst time that the food was knowingly ingested, so previous
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through breast-milk, or by another route of exposure, such as topical ex-
posure. Ezcema is a risk factor that strongly associated with food aller-
gies (Martin et al., 2015). Infants presenting with eczema were 11
times more likely to present peanut allergy and 6 times more likely to
have egg allergy, suggesting that alteration of the skin barrier facilitates
contactwith the allergen.Moreover, mutations in ﬁlaggrin, a protein es-
sential to maintain skin barrier, have been associated with increased
risk of food allergy (Brown et al., 2011).
High levels of environmental exposure to peanut due to household
consumption during infancy have been related with sensitization (Fox
et al., 2009). There is a positive correlation between high peanut con-
sumption and the presence of peanut proteins in the house dust
(Brough et al., 2013; Trendelenburg et al., 2013), which has also been
shown for other allergens including ﬁsh, milk or egg (Bertelsen et al.,
2014). These peanut dust proteins are biologically active and able to ac-
tivate immune system cells (Brough et al., 2013). In addition, the use in
infants of preparations containing peanut oil has been associated with
peanut allergy (Lack et al., 2003) and the same association has been
found between wheat allergy and exposure to wheat protein in facial
soap (Fukutomi et al., 2014). Immune proﬁling of allergen-responsive
T cells also supports the hypothesis of skin priming. T cells from
peanut-allergic individuals that expressed the skin-homing marker cu-
taneous lymphocyte antigen (CLA) had increased proliferation to pea-
nut compared to those expressing β7, one component of the α4β7
gastrointestinal-homing molecule (Chan et al., 2012). Similarly, CD4+
T cells from peanut-allergic individuals that were reactive to the peanut
allergen Ara h 1, identiﬁed using Ara h 1-speciﬁc tetramers, expressed
the skin-homing marker CCR4 but low levels of β7 (Delong et al.,
2011). These homing receptor studies are supportive of the concept of
skin priming.
Although environmental peanut exposure has been postulated as a
risk factor for food allergies, exposure to allergens via the skin does
not by default lead to sensitization. For example, mice exposed to milk
or soy allergens by topical application only develop sensitization when
exogenous adjuvants are co-administered (Dunkin et al., 2011;
Tordesillas et al., 2014). Staphylococcal enterotoxin B (SEB), which is
found to be produced by bacteria colonization lesional skin in patients
with atopic dermatitis (Boguniewicz and Leung, 2010), can promote
topical sensitization to foods inmice (Tordesillas et al., 2014). Other fac-
tors that promote sensitization through the skin include damage, such
as that caused by tape stripping that models damage induced by
scratching in eczema. Some allergens can induce sensitization in the ab-
sence of any exogenous adjuvant or damage. Peanut or tree nuts can in-
duce sensitization when applied topically on the skin without any
external adjuvant, which in the case of peanut was shown to be due
to intrinsic adjuvant activity (Tordesillas et al., 2014).
Innate immune responses in the skin are critical for promoting sen-
sitization to foods. Tape stripping upregulates TSLP which acts on skin
DCs to promote Th2 skewing (Han et al., 2014). Peanut exposure drives
Th2 cell induction by inducing IL-33 production from keratinocytes,
which subsequently modiﬁes the phenotype of skin-draining dendritic
cells through its receptor ST2 (Tordesillas et al., 2014). Inmodels driven
by adjuvants or skin damage, TSLP, IL-6, and IL-1β contribute to the gen-
eration of Th2 and Tfh cells (Noti et al., 2013; Tordesillas et al., 2014).
Thus, multiple immunemechanisms by a variety of environmental trig-
gers can lead to Th2 skewing and IgE production when allergen expo-
sure occurs via the skin.
The dual exposure hypothesis of food allergy proposes that exposure
through the skin promotes sensitization, while early exposure through
the gastrointestinal tract is tolerogenic. This is supported by clinical
ﬁndings that early consumption of food, such as peanuts, ﬁsh or
wheat is associated with a lower incidence of food allergy (Du Toit
et al., 2008; Kull et al., 2006; Poole et al., 2006). To directly assess the im-
pact of early oral introduction, infants with eczemawere randomized to
ingest egg or placebo at 4months of age (Palmer et al., 2013). Therewasa trend toward lower frequency of egg allergy in the group that received
dietary egg. However, there was a high frequency of children already
clinically reactive to egg at 4 months. Early introduction of dietary pea-
nut was tested in the LEAP (Learning Early about Peanut Allergy) study
(Du Toit et al., 2015). Introduction of peanut in the diet of infants at high
risk for peanut allergy (beginning at ages 4–11months) was associated
with a dramatically reduced frequency of peanut allergy compared to
avoidance. To determine if this clinical response was consistent with
sustained immune tolerance, subjects strictly avoided peanut for a
year before being re-evaluated for peanut allergy. Results showed a
sustained protection from peanut allergy in those who had ingested
peanut early in life (Du Toit et al., 2016). Expanding the early dietary in-
troduction to a general population and including 6 foods (EAT study)
showed no signiﬁcant effect in an intention-to-treat analysis, but did
show a suppression of peanut and egg allergy in a per-protocol analysis.
The investigators reported that compliance in introducing all 6 foods
was poor, indicating that introduction of a diverse set of foods in early
life may not be a simple task (Perkin et al., 2016). The tolerogenic re-
sponse to foods encountered through the gastrointestinal route in
early life is consistent with the concept of oral tolerance, which is a
state of antigen-speciﬁc systemic unresponsiveness that is mediated
by Tregs educated by a tolerogenic population of gastrointestinal DCs
(Berin and Shrefﬂer, 2016). See Fig. 1 for a schematic illustrating the
site-dependent hypothesis of food allergy and tolerance.
5. Role of the intestinal microbiota in susceptibility to food allergy
Epidemiologic factors protective against food allergy includes having
older siblings and pet exposure in early life (Peters et al., 2015). Pet
ownership is associated with a highmicrobial diversity in the home en-
vironment (Fujimura et al., 2010) and administration of dust from pet-
owning home intomicewas shown to be protective against experimen-
tal asthma (Fujimura et al., 2014). The early life colonization of the gas-
trointestinal tract by bacteria important for normal immune
development is also affected by factors including mode of delivery and
dietary intake, which have been shown to alter risk of food allergy.
The fetal gut is believed to be sterile, although several reports have
described meconium (ﬁrst infant stool) microbiota composition, sug-
gesting that microbial colonization may begin already in utero (Moles
et al., 2013; Gosalbes et al., 2013). The four major bacteria phyla in the
intestine (Actinobacteria, Bacteroides, Firmicutes, and Proteobacteria)
have been found in meconium. Experimental studies in pigs indicate
that the establishment and development of a normal gut microbiota
and immune system require continuous microbial exposure during
the ﬁrst months of life, and that can be compromised by excessive hy-
giene (Schmidt et al., 2011). It has been suggested that the composition
and diversity stabilize and reach the level of adult microbiota within the
ﬁrst three years of life (Yatsunenko et al., 2012).
To determine if early life microbiota could inﬂuence the develop-
ment of food allergy, a prospective study assessed fecal microbial com-
position by 16S rRNA sequencing at 3 and 12 months of life and
compared infants with and without food sensitization (Azad et al.,
2015). Low fecal microbial richness at 3 months preceded food sensiti-
zation as measured at 12 months, whereas concurrent richness at
1 yearwas not associatedwith food sensitization (Azad et al., 2015). En-
terobacteriaceae were overrepresented while Bacteroidaceae were un-
derrepresented in food sensitized infants. Bacteroidaceae have been
described as a dominant feature of a mature intestinal microbiota, and
therefore these ﬁndings suggest a delayed maturation of the food aller-
gic microbiota. These ﬁndings were consistent with previous studies
where lowmicrobial diversity in early infancy (1week and 1month, re-
spectively) was found to predict atopic dermatitis (Wang et al., 2008;
Abrahamsson et al., 2012), and suggest that the composition ofmicrobi-
ota in early life contributes to susceptibility to food allergy.
Cross-sectional studies comparing the intestinal microbial composi-
tion of food allergic to healthy subjects have also been performed. Fecal
Fig. 1.Allergen exposure through the skin in the presence of skin damage, ﬁlaggrinmutation or bacterial toxins (SEB) promotes sensitization. Depending on the nature of the allergen and
adjuvant, epithelial cells produce cytokines that instruct dendritic cells on the skin. They transport the antigen to the skin-draining lymph nodes, where Th2 and T follicular helper (Tfh)
cells are generated and promote IgE class-switching. Antigen exposure by oral route leads to tolerance. CX3CR1+ macrophages sample antigen from the lumen and transfer it to
CD103+DCs that transport the antigen to themesenteric lymph nodes and promote the induction of Tregs. Oral tolerance can prevent the development of sensitization through the skin.
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study differences between children with food allergy (n = 17 with
IgE-mediated food allergy, n=17with non-IgE-mediated food allergy)
and healthy controls (n = 45) (Ling et al., 2014). There was no differ-
ence in microbial diversity between groups. Subjects with IgE-
mediated food allergy had increased levels of Clostridium sensu stricto
and Anaerobacter and decreased levels of Bacteroides and Clostridium
XVIII (Ling et al., 2014). Levels of Clostridium sensu stricto also correlated
with levels of IgE. Hua et al recently reported ﬁndings from the publical-
ly available AmericanGut Project (Hua et al., 2016). Of 1879participants
(primarily adult, mean age 45 years), 2.5% self-reported allergy to
peanuts, 3.2% to tree nuts, 2.6% to shellﬁsh, and 9.1% to other foods.
There was a marked reduction in microbial richness and alpha diversity
(i.e. number of taxa) in those self-reporting peanut or tree nut allergy
compared to those without peanut or tree nut allergy. There were also
signiﬁcant differences in beta diversity (i.e. composition of themicrobi-
ota) in those with peanut or tree nut allergy. In contrast to the previous
study, there were increases found in Bacteroides in thosewith peanut or
tree nut allergy. The compositional differences found were not unique
to food allergy, and were also associated with seasonal allergies. As
with any cross-sectional design, it is not possible to assess causation
between changes in microbial composition and food allergy.
It has been demonstrated that commensal bacteria regulate the pro-
duction of IgE. Germ-free mice have increased levels of IgE, and coloni-
zation of germ-free mice with a diverse microbial population during a
critical window early in life suppresses IgE and prevents mice from de-
velopment of food allergy (Cahenzli et al., 2013). There is evidence that
a difference in microbial composition can increase susceptibility to food
allergy. Mice genetically susceptible to food allergy exhibit a speciﬁc gut
microbiota signature capable of transmitting disease susceptibility
(Noval Rivas et al., 2013). In this study, the authors showed that food
allergy-prone mice with a gain-of-function mutation in the IL-4receptor a-chain (Il4raF709) are susceptible to oral sensitization with
OVA. OVA-sensitized Il4raF709 mice exhibited a speciﬁc intestinal
microbiota signature, which could be transferred to germ free mice by
oral administration of fecal pellets. Recipient mice then developed sus-
ceptibility to food allergy (Noval Rivas et al., 2013). Commensal organ-
isms that are protective against development of food allergy have
been identiﬁed. Indigenous Clostridium species promoted Treg cell accu-
mulation in the large intestine of mice, and inoculation of either mouse
or human Clostridia strains attenuated disease in amousemodel of food
allergy (Atarashi et al., 2011; Atarashi et al., 2013). Similarly, selective
colonization of germ free mice with a clostridia-containing microbiota
protected against sensitization to peanut (Stefka et al., 2014). In addi-
tion to Clostridium species, other bacterial strains have also been iden-
tiﬁed to induce Tregs in the gastrointestinal tract (Faith et al., 2014).
The protective effect of commensal organisms has been shown to be
regulated by metabolic products, such as short chain fatty acids
(Smith et al., 2013), suggesting that factors such as high ﬁber diet that
also promote short chain fatty acidsmay have a similar protective effect.
Although the focus of studies to date has been on the composition of the
intestinal microbiota, the skin also hosts an underappreciated commen-
sal microbiota that regulates the immune tone of the skin (Naik et al.,
2015) and may contribute to food allergy.
6. Role of dietary factors
The relationship between diet during infancy (other than the
allergenic food itself) and development of allergic diseases remains
poorly understood. Exposure to an increased diversity of foods in early
life is inversely associated with allergic diseases including food allergy
(Roduit et al., 2014). But there are relatively few studies identifying
speciﬁc dietary components that might be a risk for the development
of food allergy.
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tion of both. The bacterial composition of the breastmilk varies depend-
ing on maternal dietary habits, the genetic background, and
demographic factors. Cessation of breastfeeding is a more signiﬁcant
factor in the composition of the intestinal microbiota than the introduc-
tion of solid foods (Backhed et al., 2015). In addition to modulating mi-
crobiota, breast milk is an immunologically complex solution that
confers immunological protection when the infant's immune system is
immature. Breast milk-derived immunomodulatory and protective
properties have been linked to several components, including immuno-
globulins, glycoconjugates and oligosaccharides, antioxidants and fatty
acids, glutamine and dietary nucleotides, hormones, growth factors,
and cytokines. There is a lack of unifying immune evidence on the im-
pact of breastfeeding on development of food allergy (Matheson et al.,
2012). Levels of immunomodulatory cytokines including those that
modulate IgA production are different in the breast milk of mothers
whose infants develop cow's milk allergy versus those who do not
(Jarvinen et al., 2015). Furthermore, dietary cow's milk avoidance by
mothers is associated with low cow's milk-speciﬁc IgA in breast milk,
low cow's milk-speciﬁc IgG and IgA in infant serum, and development
of cow's milk allergy in infants (Jarvinen et al., 2014). Reverse causation
(changing of maternal diet or breastfeeding in response to symptoms in
the infant) is a major confounding factor in studies of the role of breast
milk on development of food allergy, and prospective studies are need-
ed to determine causation.
Vitamin D deﬁciency is associated with food sensitization (Baek
et al., 2014), as well as IgE-mediated food allergy (Allen et al.,
2013). Infants from Australian-born parents with vitamin D insufﬁ-
ciency had increased likelihood of egg and peanut allergy (AllenFig. 2.Microbiota and diet inﬂuence the development of allergy and tolerance. Microbial diversi
including Clostridia have been shown to suppress allergy, and to enhance the generation of Treg
can promote food allergy, suggesting the role of pro-allergic bacteria. Nutrients including vita
oligosaccharides can also suppress food allergy through enhancement of regulatory responses.et al., 2013). By contrast, elevated levels of vitamin D during preg-
nancy and at birth have been associated with high risk of food allergy
(Weisse et al., 2013). The frequency of food allergy/anaphylaxis is
higher at higher absolute latitudes where there is insufﬁcient UVB
intensity in the autumn and winter months for adequate vitamin D
synthesis (Mullins and Camargo, 2012). Low vitamin D results in
compromised barrier function, altered microbial composition of the
gut, and together with effects on antigen presenting cells and T
cells predisposes an individual to allergic responses to food allergens
(Vassallo and Camargo, 2010).
Other dietary factors that suppress food allergy include aryl hydro-
carbon receptor ligands, found in cruciferous vegetables such as cab-
bage, Brussels sprouts, and broccoli (Schulz et al., 2011). Ingestion of
n−3 long chain polyunsaturated fatty acids (PUFA), and non-
digestible oligosaccharides can also suppress food allergy in mice
through induction of Tregs (Schouten et al., 2012; Van Den Elsen et al.,
2013). Dietary factorsmay be directly immunomodulatory, or may sup-
press food allergy through modulation of the intestinal microbiota (Wu
et al., 2011). See Fig. 2 for a schematic illustrating the role of microbiota
and the diet in allergy and tolerance to foods.7. Emerging treatments for food allergy
Currently the standard of care for food allergy is strict food avoid-
ance and use of epinephrine injection pens for accidental exposures.
As discussed in previous sections, prevention strategies can be highly ef-
fective but once allergy is established immune tolerance through inter-
vention is difﬁcult to achieve.ty suppresses IgE class-switching,which occurswithin the Peyer's patch. Strains of bacteria
s and improve epithelial barrier function. There is also evidence thatmicrobial composition
min D, aryl hydrocarbon receptor (AHR) ligands, polyunsaturated fatty acids (PUFA) and
32 S. Benedé et al. / EBioMedicine 7 (2016) 27–347.1. Allergen Immunotherapy
Allergen immunotherapy is an approach to desensitization in which
increasing amounts of allergen are administered to reduce reactivity of
allergic effector cells. Oral immunotherapy (OIT) provides effective
desensitization allowing the majority of subjects to pass a full food
challenge after 2–4 years of treatment. Persistent adverse reactions
leading to immunotherapy termination occur in approximately
10–20% of subjects (Burks et al., 2012; Narisety et al., 2015). A high
proportion of individuals who achieve desensitization develop clinical
reactivity if treatment is stopped {Vickery, 2014 #30}. The use of anti-
IgE (omalizumab) together with OIT was recently reported to improve
the safety of OIT without having signiﬁcant effects on long term efﬁcacy
(Wood et al.). Other routes of immunotherapy, including the sublingual
and epicutaneous routes, demonstrate increased safety in comparison
to OIT, but at a cost of lower efﬁcacy (Keet andWood, 2014). Other ap-
proaches to improve safety include the use of allergens with mutated
IgE binding sites (Wood et al., 2013), peptides lacking the ability to
cross-link IgE (Kulis et al., 2012), and allergens chemically modiﬁed to
destroy conformational epitopes (van Hoffen et al., 2014).
The mechanisms by which allergen immunotherapy leads to clinical
protection involves the production of blocking antibodies such as IgA
and IgG4 (Vickery et al., 2014), reduction in basophil andmast cell reac-
tivity, generation of regulatory T cells (Syed et al., 2014) and an altered
DC phenotype facilitating increased Treg generation and reduced Th2
skewing (Syed et al., 2014; Gorelik et al., 2015). The mechanism of
this altered DC phenotype is poorly understood, but human DCs have
the capacity to respond to allergens via surface expression of a form of
the high afﬁnity IgE receptor FcεRI.
7.2. Adjuvants and Immunomodulation
To date, immunotherapy has primarily been administered as aller-
gen in the absence of other immunomodulation. Bacterial vectors carry-
ing peanut allergens failed in human trials due to reactions to the
therapy (Wood et al., 2013), despite many strategies to improve safety
including allergen modiﬁcation, bacterial encapsulation, and intrarectal
delivery. The immune consequence of administrationwas not studied in
detail. Other approaches include the use of CpG, either as a soluble
adjuvant (Kulis et al., 2013) or encapsulated with allergen within nano-
particles (Pali-Scholl et al., 2013). Inhibition of themTOR signalingpath-
way with rapamycin has been shown to suppress food allergy in mice
(Yamaki and Yoshino, 2012), and recently it was shown that selective
delivery of antigen plus rapamycinwithin nanoparticles could effective-
ly prevent, and partially treat, food-induced anaphylaxis through induc-
tion of regulatory mechanisms (Maldonado et al., 2015). The use of
autologous cells as regulatory adjuvants has been demonstrated using
allergen-coated splenocytes in mice, which effectively prevents, and
partially treats, peanut-induced anaphylaxis (Smarr et al., 2011).
7.3. Microbial therapies
The ﬁnding that Clostridia strains can suppress allergy in mice
(Stefka et al., 2014; Atarashi et al., 2013) suggests the potential use of
microbial therapeutics to enhance the development of tolerance when
given with allergen immunotherapy. The probiotic Lactobacillus
rhamnosusGGwas recently used togetherwith peanut OIT to effectively
induce desensitization compared to placebo, but no OIT group was in-
cluded as control so it is unclear if there was added efﬁcacy due to the
probiotic (Tang et al., 2015). There is currently a great interest in the po-
tential of microbial therapeutics to prevent or treat allergic diseases.
7.4. Future directions
Prevalence of food allergy, particularly peanut allergy, has risen re-
markably in the last decades, leading to investigation of contributingenvironmental factors. Diet and composition of the microbiota are two
major inter-related factors that canmodify susceptibility to food allergy.
Future studies focusing on the intestinal microbiota are needed in
human subjects and mousemodels to develop rational microbial thera-
peutics (next-generation probiotics) for the prevention of food allergy.
In addition to the intestinal microbiota, the commensal microbiota of
the skin needs to be addressed since there is growing evidence that
the skin is a site of sensitization to foods. Allergen immunotherapy by
the oral, sublingual, or epicutaneous routes show differing levels of
efﬁcacy and safety. Studies are needed to test the feasibility of adjuvants
(or microbial therapeutics) to optimize the tolerogenic potential of al-
lergen immunotherapy, as well as novel delivery vehicles or allergen
modiﬁcations to improve safety.
8. Search strategy and selection criteria
Data for this reviewwere identiﬁed by searches in PubMed. The ref-
erences were selected based on the most impactful journals and, when
possible, published in the last 5 years. Only articles published in English
were included.
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